Burkholderia cenocepacia is a serious opportunistic pathogen for Cystic Fibrosis (CF) patients, resistant to numerous antibiotics. In order to extend the life expectancy of patients, it is mandatory to control B. cenocepacia infections, even if the drug therapy is long and expensive. Besides new antimicrobials, advanced formulation strategies are highly desirable to locally treat the infections. Two new molecules have been shown to be effective against B. cenocepacia: a pyridine compound (11026103) and a benzothiadiazol derivative (10126109). Due to their chemical properties, they need to be adequately formulated for translation in vivo. The objectives of the project are to study the mechanism of action of the two compounds; to develop safe and effective inhalable formulations and to test their efficacy against B. cenocepacia wt and Bcc clinical isolates; to test toxicity on bronchial epithelial cells and mouse models.